A Comparison of Metabolic-Associated Fatty Liver Disease and Steatotic Liver Disease in a Cohort of Egyptian People Living with Human Immunodeficiency Virus.
Fatma Elrashdy, Rahma Mohamed, Ahmed Cordie, Hossam Abdel Aziz, Naema Mohamed, Ahmed Kamel, Ahmed Ramadan, Mohamed Hamdy, Maryam Yasser, Safa Meshaal, Shereen Abdel Alem, Aisha Elsharkawy, Gamal Esmat
Author Information
Fatma Elrashdy: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Rahma Mohamed: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed Cordie: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt. ORCID
Hossam Abdel Aziz: Hepatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Naema Mohamed: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed Kamel: Clinical Pharmacy Department, Faculty of pharmacy, Cairo University, Cairo, Egypt.
Ahmed Ramadan: Department of Chemical & Biotechnology Engineering, Faculty of Engineering, Université de Sherbrooke, Sherbrooke, Canada. ORCID
Mohamed Hamdy: Infectious Disease Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Maryam Yasser: MARC CRO, Cairo, Egypt.
Safa Meshaal: Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Shereen Abdel Alem: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Aisha Elsharkawy: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Gamal Esmat: Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
The prevalence of fatty liver disease in people living with human immunodeficiency virus (PLHIV) is significantly higher than in general population. This study aims to compare the burden of fatty liver disease in Egyptian PLHIV using both metabolic dysfunction-associated fatty liver disease (MAFLD) and steatotic liver disease (SLD) criteria. A retrospective cross-sectional study was conducted on PLHIV attending the HIV reference center at Embaba Fever Hospital in Egypt between November 2019 and July 2021. Data collection included demographics, comorbidities, physical examination, laboratory tests, liver ultrasound, controlled attenuation parameter, and liver stiffness measurement using Fibroscan®. The prevalence of SLD and MAFLD was 26.92% and 21.15%, respectively. The concordance between MAFLD and SLD definitions was low (kappa = 0.465). The presence of SLD was significantly associated with increased odds of significant fibrosis ( = 0.045). However, MAFLD was not significantly associated with fibrosis ( = 0.369). SLD demonstrates a stronger association with significant fibrosis than MAFLD in PLHIV. This highlights the potential of SLD as a more inclusive and representative classification for steatosis in PLHIV.
